Literature DB >> 3625482

A note on confidence intervals with extended least squares parameter estimates.

L B Sheiner, S L Beal.   

Abstract

It has previously been shown that the extended least squares (ELS) method for fitting pharmacokinetic models behaves better than other methods when there is possible heteroscedasticity (unequal error variance) in the data. Confidence intervals for pharmacokinetic parameters, at the target confidence level of 95%, computed in simulations with several pharmacokinetic and error variance models, using a theoretically reasonable approximation to the asymptotic covariance matrix of the ELS parameter estimator, are found to include the true parameter values considerably less than 95% of the time. Intervals with the ordinary least squares method perform better. Two adjustments to the ELS confidence intervals, taken together, result in better performance. These are: (i) apply a bias correction to the ELS estimate of variance, which results in wider confidence intervals, and (ii) use confidence intervals with a target level of 99% to obtain confidence intervals with actual level closer to 95%. Kineticists wishing to use the ELS method may wish to use these adjustments.

Mesh:

Substances:

Year:  1987        PMID: 3625482     DOI: 10.1007/BF01062941

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  3 in total

1.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

2.  The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data.

Authors:  C C Peck; L B Sheiner; A I Nichols
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

3.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04
  3 in total
  9 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

3.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

4.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

5.  Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach.

Authors:  H S Pentikis; J D Henderson; N L Tran; T M Ludden
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

6.  Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

7.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

8.  Clinical pharmacology with confidence.

Authors:  P C Waller; P R Jackson; G T Tucker; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

9.  Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.

Authors:  R Miller; T M Ludden
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.